Drug products: AZARGA, AZOPT, Brinzolamid Ebb, Brinzolamid Stada, Brinzolamide 2care4, Brinzolamide Accord, Brinzolamide Orifarm, Brinzolamide Sandoz, Brinzolamide/Timolol Abacus Medicine, Brinzolamide/Timolol Accord, Brinzolamide/Timolol STADA, SIMBRINZA
ATC code: S01EC04, S01EC54, S01ED51
One study showed that addition of brinzolamide to timolol treatment resulted in a similar reduction of the intraocular pressure in men and women.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of brinzolamide eyedrops have been found.
A prospective open-label study during six months where 119 glaucoma patients (56 men, 63 women) were switched from timolol to brinzolamide /timolol fixed combination showed that the median intraocular pressure decreased from 20 to 16 mmHg similarly in men and women .
According to The European Medicines Agency, Summary of Product Characteristics (SmPC) of Azarga and Azopt, an uncommon side effect could be male sexual difficulty (may affect up to 1 in 100 people) [11, 12].
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
In a population-based survey study including a medical examination in 4744 Australians, 2.3% were previously diagnosed with ocular hypertension or open angle glaucoma (52 male, 56 female). The proportion reporting a history of glaucoma surgery or treatment with glaucoma medication was similar in men and women .
In a study from the US nearly half of the individuals who had filled one glaucoma prescription discontinued the treatment within six months. Among glaucoma patients aged 40-49 years, living in the Southeast region of the US and being a woman were factors associated with discontinuation .
General differences between men and women with glaucomaIn a randomized clinical trial of normal-tension glaucoma patients, an untreated subset of patients (61 men, 99 women) was analyzed regarding risk factors for (a high) progression rate of visual field loss. The time to measurable decrease in visual field was shorter in women than in men (1849 vs. 2356 days and the speed of deterioration was higher in women than in men (0.47 vs. 0.23 decibels per year). Migraine and optic disk hemorrhage were other risk factors for an increased progression rate (OR 2.58 and 2.72, respectively). According to the authors, it could be wise to treat women with migraine or optic disk hemorrhage aggressively as they are at a higher risk of faster progression than others .An eye examination of a West Greenland Eskimos population > 40 years old (162 men, 182 women) aimed at detecting primary angle-closure glaucoma (PACG) showed a higher prevalence in women than in men (age-group 60-69: 5% in men, 15% in women and age-group 70+: 3% in men, 27% in women) . Measurements of the right eyes (155 men, 156 women) showed that the limbal chamber depth (LCD), as well as the axial chamber depth (ACD) was lower in women than in men .In a population based study in the Netherlands it was noted that women who were postmenopausal before the age of 45 had a higher risk of open-angle glaucoma (odds ratio 2.6) compared to those who were older at menopause (odds ratio for open angle glaucoma of 1.1) . A study of endothelial nitric oxide synthase gene variants found an association with open angle glaucoma which might explain this . Studies on the effect of hormonal replacement therapy (HRT) are lacking .In a retrospective study, glaucoma patients (64 men, 59 women) underwent selective laser trabeculoplasty (SLT). The intra ocular pressure (IOP) lowering efficacy of SLT was equal in men and women and regardless of type, or absence of glaucoma medication at 6 months post-laser .
Date of litterature search: 2015-12-02
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson